Invesco
RLMD icon

Invesco’s Relmada Therapeutics RLMD Stock Holding History

Invesco’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$621K Buy
89,671
+67,229
+300% +$470K ﹤0.01% 3159
2026
Q1 		$156K Buy
+22,442
New +$106K ﹤0.01% 3551
2022
Q4 		– Sell
-114,245
Closed -$4.23M – 4058
2022
Q3 		$4.23M Buy
114,245
+103,578
+971% +$2.87M ﹤0.01% 2318
2022
Q2 		$203K Buy
10,667
+1,545
+17% +$33.7K ﹤0.01% 3720
2022
Q1 		$247K Buy
+9,122
New +$189K ﹤0.01% 3718
2021
Q1 		– Sell
-267,155
Closed -$8.57M – 3934
2020
Q4 		$8.57M Buy
267,155
+2,190
+0.8% +$75.3K ﹤0.01% 1888
2020
Q3 		$9.97M Sell
264,965
-57,776
-18% -$2.23M ﹤0.01% 1654
2020
Q2 		$14.4M Buy
322,741
+56,623
+21% +$2.39M 0.01% 1433
2020
Q1 		$9.08M Sell
266,118
-3,119
-1% -$126K ﹤0.01% 1576
2019
Q4 		$10.5M Buy
+269,237
New +$8.18M ﹤0.01% 1738

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco's RLMD Position: Q2 2026 in Review

Invesco increased its Relmada Therapeutics (RLMD) stake by 300% in Q2 2026, buying an estimated $470K and bringing the position to 89,671 shares worth $621K. The position accounts for ﹤0.01% of the portfolio, ranked #3159.

Invesco first reported a position in RLMD in Q4 2019 and has held it in 10 quarters since. The position peaked at $14.4M in Q2 2020. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Invesco held 89,671 shares of Relmada Therapeutics worth $621K as of Q2 2026.
  • Invesco bought 67,229 Relmada Therapeutics shares in Q2 2026, an estimated $470K.
  • Relmada Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3159 holding.
  • Invesco first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 10 quarters since.
  • Invesco's Relmada Therapeutics position peaked at $14.4M in Q2 2020.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.